1 	|BT| (NP (NP (JJ Paired) (NN box) (NN gene) (CD 5) (JJ novel) (NN tumor) (NN suppressor) (JJ hepatocellular) (NN carcinoma) (NN interaction) (NN p53) (NN signaling) (NN pathway))) |ET| |BS|2:G05.360.340.024.340.375.249.385 6:G05.360.340.024.340 69:G02.111.087.800 104:C04.557.470.200.025.255 126:G02.111.087.800 206:G05.360.340.024.340.375.249 243:D12.776.260.645.500 259:D12.776.395.240.150.500|ES| 7:1 9:1 12:1 19:1 195:1 303:1 304:1 383:1 578:1 618:1 700:1 891:1 1918:1 2166:1
1 	|BT| (NP (NP (NNP Parkin) (NN tumor) (NN suppressor) (NN gene) (JJ hepatocellular) (NN carcinoma))) |ET| |BS|104:C04.557.470.200.025.255 206:G05.360.340.024.340.375.249|ES| 7:1 9:1 19:1 303:1 304:1 700:1 2167:1
1 	|BT| (S (NP (NP (NNP PIRC) (NN rat)) (PRN (-LRB- -LRB-) (NP (NP (NN F344/NTac-Apc)) (PRN (-LRB- -LRB-) (NP (NN am1137)) (-RRB- -RRB-))) (-RRB- -RRB-))) (NP (VBN mutated) (NN Apc) (NN gene)) (ADVP (RB spontaneously)) (VP (VB develop) (NP (NN colon)) (NP (NN tumor)) (ADVP (RB thus)) (VP (NP (VBG mimicking) (JJ familial) (NP (NP (JJ adenomatous) (NN polyposis) (-LRB- -LRB-) (NN FAP) (-RRB- -RRB-) (JJ sporadic) (JJ colorectal) (NN cancer)) (PRN (-LRB- -LRB-) (NP (NN CRC)) (-RRB- -RRB-))) (RB closely) (JJ Apc-based) (JJ rodent) (NN model)) (S (VP (VBG developing) (NP (NP (NN tumor)) (ADJP (RB mostly) (JJ small)) (NN intestine))))))) |ET| |BS|3:C04.557.470.035.215.100 4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 21:G05.360.340.024.340.375.249.050 51:C04.588.274.476.411.307.180 102:C04.588.274.476.411 245:B01.050.150.900.649.865.635.505.700 246:B01.050.150.900.649.865.635.505.700 333:D01.045 514:B01.050.150.900.649.865 590:B01.050.050.199.520.760.200|ES| 7:1 9:1 10:1 14:1 17:1 18:1 19:1 57:1 58:1 72:1 113:1 229:1 245:1 280:1 356:1 590:1 648:1 725:1 750:1 849:1 854:1 855:1 1334:1 1506:1 2133:1 2168:1 2169:1 2170:1 2171:1 2172:1 2173:1 2174:1
1 	|BT| (S (NP (NP (NP (JJ Real-time) (JJ reverse) (NN transcription) (NN polymerase) (NN chain) (NN reaction)) (PRN (-LRB- -LRB-) (NP (NN RT-PCR)) (-RRB- -RRB-))) (NN analysis)) (VP (VBD demonstrated) (NP (NP (NN up-regulation) (JJ oncogenic) (NN miR-155)) (, ,) (NP (NP (NN miR-221)) (: /) (NP (CD 222))) (, ,) (NP (NP (NN miR-21) (NN down-regulation) (JJ abundant) (JJ liver-specific) (NN miR-122)) (JJ early) (NN stage) (NN hepatocarcinogenesis))))) |ET| |BS|85:G02.111.087.225 242:A03.620 249:G05.355.315.800 272:E05.393.620.500.725 279:D27.888.569.100 339:G02.111.087.880 346:E05.393.620.500.706 591:G02.111.087.847.500|ES| 2:1 10:1 14:1 19:1 257:1 394:1 487:1 661:1 768:1 896:1 900:1 939:1 941:1 953:1 1128:1 1129:1 1148:1 1175:1 1789:1 1798:1 1799:1 1911:1 2175:1 2176:1 2177:1
1 	|BT| (S (ADVP (RB Recently)) (, ,) (S (NP (NP (NN microRNA-122)) (PRN (-LRB- -LRB-) (NP (NN miR-122)) (-RRB- -RRB-))) (VP (VBD proved) (NP (NP (NN play) (JJ important) (NN role)) (NP (JJ hepatocellular) (NN carcinoma))))) (, ,) (NP (NP (NN function) (NN context) (NN breast) (NN cancer)) (PRN (-LRB- -LRB-) (NP (NN BC)) (-RRB- -RRB-))) (VP (VBP remain) (ADJP (JJ unknown)))) |ET| |BS|12:Z01.542.049 15:F01.829.316.616 30:Z01.058.290.190.800 31:D08.811.520.224.800 79:I03.450.642.693 104:C04.557.470.200.025.255 184:D13.150.650.319|ES| 2:1 10:1 14:1 18:1 19:1 23:1 31:1 33:1 238:1 303:1 304:1 902:1 1789:1 1857:1 1999:1 2178:1 2179:1 2180:1 2181:1 2182:1
1 	|BT| (S (ADVP (RB Recently)) (, ,) (NP (NP (NP (NP (NN microRNA-7)) (PRN (-LRB- -LRB-) (NP (NN miR-7)) (-RRB- -RRB-))) (NP (NP (JJ proven) (NN play) (JJ substantial) (NN role)) (NP (NN glioblastoma) (NN breast) (NN cancer)))) (, ,) (NP (NN function) (NN context) (NNP HCC))) (VP (VBP remain) (ADJP (JJ unknown)))) |ET| |BS|15:F01.829.316.616 30:Z01.058.290.190.800 31:D08.811.520.224.800 79:I03.450.642.693 104:C04.557.470.200.025.255 184:D13.150.650.319 592:C04.557.465.625.600.380.080.335|ES| 2:1 10:1 14:1 18:1 19:1 23:1 31:1 33:1 238:1 441:1 1293:1 1999:1 2178:1 2181:1 2182:1 2183:1 2184:1 2185:1 2186:1
1 	|BT| (S (NP (NN Role) (NN microRNA-155) (JJ early) (NN stage) (NN hepatocarcinogenesis)) (VP (VBD induced) (NP (JJ choline-deficient) (NN amino) (JJ acid-defined) (NN diet) (NN C57BL/6) (NN mouse)))) |ET| |BS|15:F01.829.316.616 184:D13.150.650.319 593:B01.050.050.199.520.520.420 594:D02.033.100.291.211 595:G07.203.650.240 596:E02.642.249 597:D12.125|ES| 19:1 52:1 412:1 900:1 1128:1 1129:1 1957:1 2187:1 2188:1 2189:1 2190:1 2191:1 2192:1
1 	|BT| (S (S (VP (VBN Taken) (ADVP (RB together)))) (, ,) (NP (NNS data)) (VP (VBP suggest) (SBAR (S (NP (NN ATA)) (VP (MD may) (NP (JJ broad) (NN utility) (NN treatment) (JJ HER2-overexpressed) (NN breast) (NN cancer))))))) |ET| |BS|52:E02 63:G05.360.340.024.340.375.500.791.295.305 65:D08.811.913.696.620.682.725.400.009.400 520:C10.228.140.252.190.530.060|ES| 2:1 18:1 19:1 23:1 491:1 546:1 793:1 796:1 1537:1 1538:1 1820:1 2193:1 2194:1 2195:1
1 	|BT| (S (S (VP (VBN Taken) (ADVP (RB together)))) (, ,) (NN study) (VP (VBP indicate) (SBAR (S (NP (VBN upregulated) (NN BYSL) (NN expression)) (VP (VBP play) (NP (NN role) (NN hepatocarcinogenesis))))))) |ET| |BS|15:F01.829.316.616 79:I03.450.642.693|ES| 2:1 19:1 31:1 115:1 125:1 131:1 238:1 900:1 1479:1 1537:1 1538:1 2196:1
1 	|BT| (S (S (VP (VBN Taken) (ADVP (RB together)))) (, ,) (VP (VBP result) (VP (VB identify) (SBAR (S (NP (NN downregulation) (NN miR-497) (JJ important) (NN mechanism) (NN upregulation) (NN IGF1-R) (NN CRC) (NN cell)) (VP (VBZ contributes) (NP (NN malignancy) (NN CRC)))))))) |ET| |BS|4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 41:A11 85:G02.111.087.225 249:G05.355.315.800 339:G02.111.087.880 375:Z01.639.100 598:D12.644.276.937.400 599:M01.526.799.500|ES| 2:1 19:1 49:1 94:1 101:1 162:1 245:1 595:1 832:1 845:1 902:1 1126:1 1537:1 1538:1 2197:1 2198:1
1 	|BT| (NP (NP (NP (DT The) (JJ adenomatous) (NN polyposis) (NN coli) (-LRB- -LRB-) (NN APC) (-RRB- -RRB-) (NN gene) (NN product)) (NP (VBN mutated) (JJ vast) (NN majority) (JJ human) (JJ colorectal) (NN cancer)))) |ET| |BS|55:B01.050.150.900.649.801.400.112.400.400 219:G05.360.340.024.340.375.249.320 220:D05.500.117.249|ES| 9:1 10:1 11:1 14:1 17:1 18:1 19:1 36:1 57:1 58:1 59:1 198:1 229:1 675:1 691:1 752:1
1 	|BT| (NP (NP (NP (DT The) (NN APC) (NN gene) (NN play) (JJ major) (NN role)) (NP (JJ human) (NN colon) (NN carcinogenesis)))) |ET| |BS|15:F01.829.316.616 21:G05.360.340.024.340.375.249.050 33:C04.697.098 46:A03.556.124.526.356 55:B01.050.150.900.649.801.400.112.400.400 79:I03.450.642.693|ES| 9:1 11:1 19:1 31:1 36:1 113:1 207:1 238:1 462:1 691:1
1 	|BT| (NP (NP (NP (DT The) (NN B-cell) (NN tumor) (NN promoter)) (SBAR (S (NP (NN Bcl-3)) (VP (VBZ suppresses) (NP (JJ inflammation-associated) (NN colon) (NN tumorigenesis) (JJ epithelial) (NN cell))))))) |ET| |BS|32:C04.697.098.500 33:C04.697.098 53:C06.405.205.265 75:A11.436 310:A11.063.438 600:D27.888.569.100|ES| 7:1 19:1 78:1 83:1 94:1 113:1 127:1 404:1 686:1 691:1 1849:1 2199:1
1 	|BT| (S (NP (DT The) (NP (NN c-myc) (NN oncogene) (NN play) (JJ important) (NN role)) (NN tumorigenesis)) (ADVP (RB frequently)) (VP (VBD deregulated) (NP (NP (JJ many) (JJ human) (NN cancer)) (, ,) (PP (VBG including) (NP (JJ gastrointestinal) (NN cancer)))))) |ET| |BS|9:G05.360.340.024.340.375.500 12:Z01.542.049 15:F01.829.316.616 32:C04.697.098.500 33:C04.697.098 55:B01.050.150.900.649.801.400.112.400.400 79:I03.450.642.693|ES| 2:1 18:1 19:1 24:1 31:1 36:1 78:1 183:1 238:1 455:1 561:1 691:1 698:1 902:1 1040:1 1965:1
1 	|BT| (NP (NP (DT The) (NN ECM-modulator) (NN inter)) (: -) (S (NP (NP (NN alpha-trypsin) (NN inhibitor) (JJ heavy) (NN chain) (NN family) (NN member)) (CD five) (-LRB- -LRB-) (NN ITIH5) (-RRB- -RRB-)) (ADVP (RB recently)) (VP (VBD identified) (NP (NP (NN tumor) (NN suppressor)) (VP (ADVP (RB potentially)) (VP (VBN involved) (NP (NP (VBG impairing) (NN breast) (NN cancer) (NN progression) (JJ molecular) (NN mechanism)) (VP (VBG underlying) (S (NP (NN function)) (ADJP (ADVP (RB still)) (JJ elusive))))))))))) |ET| |BS|16:C23.550.291.656 44:F01.829.263 206:G05.360.340.024.340.375.249 223:A11.284.295.310|ES| 7:1 10:1 14:1 18:1 19:1 23:1 33:1 48:1 97:1 161:1 162:1 380:1 435:1 623:1 691:1 700:1 764:1 765:1 766:1 767:1 768:1 769:1 770:1 771:1 772:1 773:1 774:1 775:1 776:1 777:1
1 	|BT| (S (NP (DT The) (NN finding) (JJ parkin-deficient) (NN mouse) (JJ susceptible) (NN hepatocarcinogenesis)) (VP (VBN provided) (VP (JJ first) (NP (NN evidence) (VP (VBG showing) (NP (JJ parkin) (ADVP (RB indeed)) (NP (NN tumor) (NN suppressor) (NN gene)))))))) |ET| |BS|11:B01.050.150.900.649.865.635.505.500 206:G05.360.340.024.340.375.249 275:C23.888|ES| 7:1 9:1 19:1 38:1 52:1 691:1 700:1 816:1 899:1 900:1 927:1 1155:1 2200:1 2201:1 2202:1 2203:1
1 	|BT| (S (NP (DT The) (NN finding)) (VP (MD may) (VP (VB provide) (NP (NP (NN basis) (NN understanding) (JJR greater) (NN predisposition) (JJ intestinal) (NN cancer) (NN Mlh1)) (PRN (-LRB- -LRB-) (: -) (: /) (: -) (-RRB- -RRB-))) (NP (NN mouse))))) |ET| |BS|11:B01.050.150.900.649.865.635.505.500 101:C04.588.274.476.411 239:F02.463.188.357 401:C23.550.291.687|ES| 10:1 14:1 18:1 19:1 45:1 52:1 109:1 491:1 586:1 691:1 711:1 905:1 927:1 1140:1 1768:1 2204:1
1 	|BT| (NP (NP (NP (DT The) (NP (NN ITF-2) (NN gene))) (JJ located) (JJ chromosomal) (NN region) (NN 18q21)) (: ;) (S (NP (JJ allelic) (NN loss) (NN locus)) (VP (VBZ occurs) (NP (ADJP (CD 70) (NN %)) (JJ colorectal) (NN cancer))))) |ET| |BS|4:C04.588.274.476.411.307 6:G05.360.340.024.340 289:A11.284.187 290:G05.365.590.029.530 292:Z01|ES| 9:1 17:1 18:1 19:1 32:1 217:1 369:1 377:1 657:1 667:1 691:1 1002:1 1475:1 2038:1 2040:1 2205:1 2206:1
1 	|BT| (NP (NP (DT The) (NN K-sam) (NN gene)) (, ,) (VP (ADVP (RB originally)) (VBN isolated) (NP (NP (VBN amplified) (NN gene) (NN stomach) (NN cancer) (NN cell) (NN line) (NN KATO-III)) (, ,) (VP (VBN characterized) (S (NP (NP (NP (JJ preferential) (NN amplification) (JJ undifferentiated) (NN type)) (PRN (-LRB- -LRB-) (NP (JJ diffuse) (NN type)) (-RRB- -RRB-))) (NN stomach) (NN cancer)) (VP (VBZ encodes) (NP (CD one) (NN receptor) (JJ heparin-binding) (NN growth) (NN factor) (NN fibroblast) (NN growth) (NN factor)))))))) |ET| |BS|6:G05.360.340.024.340 94:A11.251.210 232:D02.886.030.676.180 601:D12.644.276.624 602:D09.698.373.400|ES| 2:1 9:1 10:1 14:1 18:1 19:1 94:1 102:1 185:1 186:1 264:1 543:1 653:1 691:1 801:1 803:1 804:1 921:1 985:1 1010:1 1653:1 2207:1 2208:1 2209:1 2210:1 2211:1 2212:1 2213:1
1 	|BT| (UCP (S (NP (DT The) (NN miR-122) (JJ regulatory) (NN circuitry) (NN implication) (NN hepatocarcinogenesis)) (VP (VBN identified) (S (VP (VBG using) (NP (NN liver) (JJ different) (NN development) (NN stage)))))) (, ,) (NP (NP (NP (NP (JJ human) (JJ hepatocellular) (NN carcinoma)) (PRN (-LRB- -LRB-) (NP (NN HCC)) (-RRB- -RRB-))) (NP (NN tissue) (NN cell) (NN line)) (, ,) (NP (NP (NN aflatoxin) (NN B)) (-LRB- -LRB-) (CD 1) (-RRB- -RRB-) (-LRB- -LRB-) (NN AFB) (LST (-LRB- -LRB-) (CD 1) (-RRB- -RRB-) (-RRB- -RRB-)))) (: -) (NP (VBN transformed) (NN cell)))) |ET| |BS|41:A11 55:B01.050.150.900.649.801.400.112.400.400 94:A11.251.210 98:A10 104:C04.557.470.200.025.255 242:A03.620 603:D03.383.663.283.119.075|ES| 2:1 10:1 14:1 19:1 35:1 36:1 85:1 94:1 98:1 264:1 272:1 303:1 304:1 350:1 414:1 441:1 623:1 691:1 763:1 836:1 900:1 1129:1 1789:1 1817:1 1818:1 2214:1 2215:1 2216:1
1 	|BT| (S (NP (DT The) (NN orphan) (NN cotransport) (NN protein)) (VP (VBD expressed) (NP (NP (NP (NN SLC5A8) (NN gene) (VBN shown) (NN play) (NN role)) (NP (VBG controlling) (NN growth) (NN colon) (NN cancer))) (, ,) (NP (NN silencing) (NP (NN gene) (JJ common) (NP (JJ early) (NN event) (JJ human) (NN colon) (NN neoplasia))))))) |ET| |BS|6:G05.360.340.024.340 7:D12.776 15:F01.829.316.616 30:Z01.058.290.190.800 31:D08.811.520.224.800 42:G05.355.315.203.374 45:G07.700.320.249 51:C04.588.274.476.411.307.180 55:B01.050.150.900.649.801.400.112.400.400 79:I03.450.642.693 604:M01.108|ES| 2:1 4:1 6:1 9:1 18:1 19:1 31:1 36:1 100:1 102:1 113:1 205:1 237:1 238:1 640:1 655:1 691:1 1128:1 2217:1 2218:1 2219:1 2220:1
1 	|BT| (NP (NP (NP (DT The) (JJ potential) (NN utility) (NN acetyltanshinone) (NN IIA) (NN treatment) (JJ HER2-overexpressed) (NN breast) (NN cancer)) (: :) (NP (NP (NN Induction) (NN cancer) (NN cell) (NN death)) (VP (VBG targeting) (NP (JJ apoptotic) (JJ metabolic) (NN signaling) (NN pathway)))))) |ET| |BS|33:C04.697.098 39:G04.299.139.160 52:E02 63:G05.360.340.024.340.375.500.791.295.305 65:D08.811.913.696.620.682.725.400.009.400 69:G02.111.087.800 126:G02.111.087.800 134:G04.299.139 605:G03.495.553|ES| 18:1 19:1 23:1 94:1 104:1 195:1 383:1 411:1 546:1 616:1 691:1 827:1 2006:1 2020:1 2194:1 2195:1 2221:1 2222:1 2223:1
1 	|BT| (S (NP (NP (DT The) (NN proliferation)) (NP (JJ certain) (NP (JJ human) (JJ HER2-positive) (NN breast) (NN cancer) (NN line)))) (ADVP (RB also)) (VP (VBZ requires) (SBAR (S (NP (NP (NN HSF1)) (, ,) (NP (NN knockdown))) (VP (VBD led) (NP (NP (NN upregulation) (NN p21)) (CC and/or) (NP (NN decrease) (NN survivin))) (, ,) (S (VP (VBG precipitating) (NP (NN growth) (NN arrest))))))))) |ET| |BS|45:G07.700.320.249 55:B01.050.150.900.649.801.400.112.400.400 63:G05.360.340.024.340.375.500.791.295.305 65:D08.811.913.696.620.682.725.400.009.400 86:D01.268.556.435 249:G05.355.315.800 339:G02.111.087.880|ES| 2:1 5:1 18:1 19:1 23:1 36:1 102:1 149:1 264:1 295:1 299:1 464:1 602:1 691:1 1126:1 1135:1 2224:1 2225:1 2226:1 2227:1 2228:1 2229:1 2230:1
1 	|BT| (S (NP (DT The) (NN result)) (VP (VBP suggest) (SBAR (S (NP (NN MTHFR) (NN genotype) (JJ relevant) (JJ independent) (NN factor) (NN patient) (NN outcome) (JJ 5FU-based) (NN treatment)) (VP (VBD advanced) (NP (JJ colorectal) (NN cancer))))))) |ET| |BS|4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 50:M01.643 52:E02 333:D01.045 396:G05.380 560:D03.383.742.698.875.404 606:D08.811.682.662.290|ES| 17:1 18:1 19:1 101:1 120:1 185:1 546:1 547:1 691:1 796:1 865:1 883:1 997:1 1329:1 2231:1 2232:1
1 	|BT| (S (NP (DT The) (NN Tg737) (NN gene)) (VP (VBD found) (NP (NP (JJ altered) (ADJP (QP (RB approximately) (CD 40)) (NN %)) (JJ rodent) (JJ chemically-induced) (NN liver) (NN tumor)) (, ,) (NP (NP (CD 40) (NN %)) (JJ human) (NN liver) (NN tumor)) (, ,) (NP (NN liver)) (, ,) (NP (NN kidney) (JJ pancreatic) (JJ human) (NN tumor) (NN cell) (NN line))))) |ET| |BS|6:G05.360.340.024.340 30:Z01.058.290.190.800 31:D08.811.520.224.800 55:B01.050.150.900.649.801.400.112.400.400 242:A03.620 485:A05.810.453 514:B01.050.150.900.649.865 515:C04.588.274.623 607:A11.251.210.190 608:A03.734|ES| 2:1 7:1 9:1 19:1 36:1 37:1 94:1 264:1 369:1 467:1 582:1 691:1 693:1 836:1 1717:1 1805:1 1843:1 2173:1 2233:1
1 	|BT| (NP (NP (NP (DT The) (NN transcription) (NN factor) (NNP LSF)) (: :) (NP (JJ novel) (NN oncogene) (JJ hepatocellular) (NN carcinoma)))) |ET| |BS|9:G05.360.340.024.340.375.500 104:C04.557.470.200.025.255 166:D12.776.930 259:D12.776.395.240.150.500|ES| 19:1 24:1 104:1 185:1 303:1 304:1 487:1 691:1 891:1 2150:1
1 	|BT| (S (ADVP (RB Therefore)) (NP (NN bile) (NN duct) (NN cancer) (NN patient)) (VP (MD may) (NP (VBN treated) (NN miR-34a) (NN inhibitor) (NN Per1) (NN stimulator) (NN future)))) |ET| |BS|50:M01.643 52:E02 354:I01.320|ES| 18:1 19:1 120:1 380:1 491:1 1099:1 1190:1 1620:1 1621:1 1622:1 1623:1 1624:1 1625:1
1 	|BT| (S (ADVP (RB Therefore)) (, ,) (VP (VBP conclude) (SBAR (S (NP (NP (NN miR-141) (NN target) (NN MAP4K4)) (, ,) (VP (VBP act) (NP (NN tumor) (NN suppressor) (JJ pancreatic) (NN cancer) (NN cell))) (, ,)) (VP (MD may) (VP (VB serve) (NP (ADJP (ADJP (JJ novel)) (ADJP (JJ therapeutic))) (NN agent) (JJ miRNA-based) (JJ pancreatic) (NN cancer) (NN therapy)))))))) |ET| |BS|41:A11 52:E02 81:E02.095.465.425.400.330.050.400 184:D13.150.650.319 206:G05.360.340.024.340.375.249 259:D12.776.395.240.150.500 333:D01.045 557:D02.241.081.069.600.150|ES| 2:1 7:1 18:1 19:1 94:1 130:1 160:1 246:1 463:1 465:1 467:1 491:1 532:1 541:1 700:1 728:1 891:1 1620:1 1968:1 2234:1
1 	|BT| (S (NP (DT These) (NNS data)) (VP (VBP suggest) (SBAR (S (NP (NN HNF4alpha)) (VP (VBZ maintains) (NP (NP (NN hepatocyte) (NN differentiation) (JJ adult) (JJ healthy) (NN liver)) (, ,) (S (NP (NN loss)) (VP (MD may) (ADVP (RB directly)) (VP (VB contribute) (NP (JJ hepatocellular) (NN carcinoma) (NN development))) (, ,) (S (VP (ADVP (RB thus)) (VBG indicating) (NP (NN factor) (JJ possible) (NN liver) (NN tumor) (NN suppressor) (NN gene)))))))))))) |ET| |BS|74:G04.299.151 104:C04.557.470.200.025.255 119:M01.060.116 188:N02.628 206:G05.360.340.024.340.375.249 242:A03.620 262:A11.436.348 571:N01.400|ES| 2:1 7:1 9:1 19:1 32:1 35:1 123:1 185:1 215:1 303:1 304:1 355:1 450:1 491:1 621:1 631:1 700:1 792:1 793:1 796:1 836:1 1334:1 1359:1 1909:1 2235:1 2236:1
1 	|BT| (S (NP (DT These) (VBG finding) (NP (VBN suggested) (NN Notch1) (NN signaling))) (VP (VBP play) (NP (NP (NP (JJ important) (NN role) (NN maintenance) (NN cancer)) (JJ stem-like) (NN phenotype) (JJ diffuse) (NN type) (JJ gastric) (NN cancer) (NN RBP-Jkappa) (JJ dependent) (NN pathway)) (VP (VBG inhibiting) (NP (NN Notch1) (NN signaling)))) (VP (MD could) (NP (JJ effective) (NN therapy) (NN CD133) (JJ positive) (JJ diffuse) (NN type) (JJ gastric) (NN cancer))))) |ET| |BS|12:Z01.542.049 15:F01.829.316.616 52:E02 69:G02.111.087.800 79:I03.450.642.693 80:G05.695 122:C14.280.383 188:N02.628 309:A18.024.937|ES| 18:1 19:1 31:1 86:1 130:1 195:1 233:1 236:1 238:1 321:1 383:1 543:1 651:1 652:1 653:1 792:1 880:1 902:1 908:1 925:1 927:1 1062:1 1063:1 1638:1 1639:1
1 	|BT| (S (NP (DT These) (NN study)) (VP (VB establish) (NP (NP (JJ key) (NN role) (NN LSF) (NN hepatocarcinogenesis) (NN usher) (JJ novel) (JJ therapeutic) (NN avenue)) (NP (NNP HCC))) (, ,) (NP (RB invariably) (JJ fatal) (NN disease)))) |ET| |BS|15:F01.829.316.616 52:E02 104:C04.557.470.200.025.255 259:D12.776.395.240.150.500 288:C23.550.288|ES| 2:1 19:1 31:1 131:1 159:1 220:1 441:1 541:1 792:1 891:1 900:1 998:1 1655:1 2150:1 2237:1 2238:1 2239:1
1 	|BT| (S (NP (NP (DT This) (JJ first) (NN study)) (VP (VBG showing) (NP (NN miR-205)))) (VP (VBZ inhibits) (NP (JJ proto-oncogenic) (NNS SFKs)) (, ,) (S (VP (VBG indicating) (NP (JJ therapeutic) (JJ potential) (NN miR-205) (NN treatment) (JJ renal) (NN cancer)))))) |ET| |BS|52:E02 122:C14.280.383 279:D27.888.569.100|ES| 2:1 18:1 19:1 131:1 541:1 546:1 615:1 807:1 816:1 827:1 922:1 2201:1 2236:1 2240:1 2241:1 2242:1
1 	|BT| (S (NP (DT This)) (VP (VBD led) (SBAR (S (NP (NN u)) (VP (VBP investigate) (SBAR (S (NP (NP (JJ antitumor) (NN growth)) (NP (JJ antimetastatic) (NN activity) (NN alpha-mangostin) (JJ immunocompetent) (NN xenograft) (NN model) (NN mouse) (JJ metastatic) (JJ mammary) (NN cancer) (NN p53) (NN mutation))) (VP (VBZ induces) (NP (NP (JJ metastatic) (NN spectrum)) (NP (JJ similar) (VBN seen) (JJ human) (NN breast) (NN cancer))))))))))) |ET| |BS|2:G05.360.340.024.340.375.249.385 10:A01.236 11:B01.050.150.900.649.865.635.505.500 18:G05.365.590 30:Z01.058.290.190.800 31:D08.811.520.224.800 45:G07.700.320.249 55:B01.050.150.900.649.801.400.112.400.400 86:D01.268.556.435 92:E04.936.764 93:A01.941.875 113:C04.697.650 213:F02.830.816.964 609:A01.236.249 610:G12.460|ES| 12:1 18:1 19:1 23:1 34:1 36:1 52:1 72:1 102:1 214:1 265:1 332:1 337:1 399:1 459:1 724:1 807:1 2228:1 2243:1 2244:1 2245:1 2246:1 2247:1 2248:1 2249:1
1 	|BT| (S (ADVP (RB Thus)) (, ,) (NP (NN inactivation) (NN TGF-beta) (NN signaling) (NN loss) (NN PTEN)) (VP (VBP cooperate) (NP (NP (NN drive) (JJ intestinal) (NN cancer) (NN formation) (NN progression)) (VP (VBG suppressing) (NP (NN cell) (NN cycle) (NN inhibitor)))))) |ET| |BS|16:C23.550.291.656 20:G03.495 30:Z01.058.290.190.800 31:D08.811.520.224.800 66:F01.658.293 69:G02.111.087.800 101:C04.588.274.476.411 353:G04.299.134 503:D12.644.276.374.687|ES| 2:1 18:1 19:1 32:1 43:1 48:1 94:1 109:1 181:1 195:1 380:1 474:1 601:1 1314:1 1691:1 1774:1 1936:1 2250:1
1 	|BT| (S (ADVP (RB Thus)) (, ,) (NP (NN MYH11) (NN mutation)) (VP (VBP appear) (VP (VBP contribute) (ADVP (RB also)) (NP (JJ human) (JJ intestinal) (NN neoplasia))))) |ET| |BS|18:G05.365.590 30:Z01.058.290.190.800 31:D08.811.520.224.800 55:B01.050.150.900.649.801.400.112.400.400 102:C04.588.274.476.411|ES| 2:1 5:1 19:1 34:1 36:1 109:1 450:1 640:1 1627:1 1691:1 2251:1
1 	|BT| (S (ADVP (RB Thus)) (, ,) (NP (NN PPARgamma1)) (VP (MD might) (VP (VB offer) (NP (JJ promising) (NN gene) (JJ therapeutic) (NN target) (NN atherosclerosis))))) |ET| |BS|52:E02 149:G05.360.340.024.340.364.875.890 511:C14.907.137.126.307 513:C14.907.137.126|ES| 2:1 9:1 19:1 160:1 541:1 798:1 1042:1 1517:1 1691:1 1803:1 1804:1
1 	|BT| (S (S (VP (TO To) (VP (VB characterize) (NP (NN CC531) (NN model) (JJ molecular) (NN level))))) (, ,) (NP (VBN screened) (NN mutation) (NN gene)) (VP (VBG covering) (NP (NP (JJ important) (NN signal-transduction) (NN pathway)) (NP (NP (VBN known) (NN play) (JJ major) (NN role) (NN colon) (NN carcinogenesis)) (, ,) (NP (NN wnt) (JJ ki-ras) (NN signaling) (NN pathway)))))) |ET| |BS|6:G05.360.340.024.340 15:F01.829.316.616 18:G05.365.590 30:Z01.058.290.190.800 31:D08.811.520.224.800 33:C04.697.098 46:A03.556.124.526.356 79:I03.450.642.693 126:G02.111.087.800 611:E05.599.595|ES| 2:1 9:1 19:1 31:1 34:1 72:1 113:1 161:1 195:1 207:1 238:1 249:1 383:1 462:1 556:1 828:1 902:1 2252:1 2253:1 2254:1 2255:1 2256:1 2257:1 2258:1
1 	|BT| (S (S (VP (TO To) (VP (VB investigate) (NP (NP (NP (NN role) (NN APC) (NN gene) (NN microsatellite) (NN instability)) (PRN (-LRB- -LRB-) (NP (NN MI)) (-RRB- -RRB-))) (JJ PhIP-induced) (NN colon) (NN carcinogenesis))))) (, ,) (NP (NN mutation) (NN APC) (NN gene) (NN alteration) (NNS microsatellites)) (VP (VBN examined))) |ET| |BS|15:F01.829.316.616 18:G05.365.590 21:G05.360.340.024.340.375.249.050 30:Z01.058.290.190.800 31:D08.811.520.224.800 33:C04.697.098 46:A03.556.124.526.356 394:G02.111.570.080.708.800.500 538:C23.550.362.590|ES| 2:1 9:1 10:1 11:1 14:1 19:1 31:1 34:1 113:1 207:1 324:1 459:1 828:1 951:1 1299:1 1332:1 1839:1 2259:1 2260:1
1 	|BT| (NP (NP (NP (NNS Tumors)) (VP (VBG lacking) (S (NP (NN DNA) (NN mismatch) (NN repair) (NN activity) (-LRB- -LRB-) (NN MMR) (-RRB- -RRB-) (NN patient)) (NP (NP (NP (JJ Hereditary) (NN Nonpolyposis) (JJ Colorectal) (NN Cancer)) (PRN (-LRB- -LRB-) (NP (NN HNPCC)) (-RRB- -RRB-))) (SBAR (S (NP (JJ sporadic) (JJ colorectal) (NN cancer)) (VP (VBD identified) (NP (NP (NN presence) (JJ high) (NN level) (NN instability) (JJ repetitive) (NN sequence)) (VP (VBN known) (NP (NP (NNS microsatellites)) (PRN (-LRB- -LRB-) (NP (NN MSI)) (-RRB- -RRB-))))))))))))) |ET| |BS|4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 8:C04 50:M01.643 174:G02.111.087.219.220 394:G02.111.570.080.708.800.500 524:C04.588.274.476.411.307.190 538:C23.550.362.590 612:G02.111.570.080.708|ES| 10:1 14:1 17:1 18:1 19:1 53:1 120:1 178:1 249:1 293:1 346:1 376:1 399:1 513:1 556:1 584:1 623:1 666:1 725:1 1299:1 1919:1 2134:1 2136:1 2260:1 2261:1 2262:1 2263:1 2264:1 2265:1
1 	|BT| (NP (NP (NNP UNLABELLED)) (: :) (NP (NP (NP (NN Loss) (NN E-cadherin)) (PRN (-LRB- -LRB-) (NP (NN CDH1)) (-RRB- -RRB-))) (, ,) (NP (NN Smad4)) (, ,) (NP (NP (NN p53) (VBN shown) (NN play) (JJ integral) (NN role)) (ADJP (JJ gastric))) (, ,) (NP (JJ intestinal) (, ,) (NN breast) (NN cancer) (NN formation)))) |ET| |BS|2:G05.360.340.024.340.375.249.385 12:Z01.542.049 15:F01.829.316.616 20:G03.495 30:Z01.058.290.190.800 31:D08.811.520.224.800 47:A03.556.124 70:A03.556.875.875 79:I03.450.642.693 613:D12.776.395.550.200.200|ES| 2:1 10:1 12:1 14:1 18:1 19:1 23:1 31:1 43:1 86:1 104:1 109:1 237:1 238:1 521:1 1788:1 2266:1 2267:1 2268:1 2269:1
1 	|BT| (S (NP (NP (NN Up-regulation) (JJ several) (NN miR-1) (NN target)) (PP (VBG including) (NP (NP (NN FoxP1)) (, ,) (NP (NN MET)) (, ,) (NP (NN HDAC4) (JJ primary) (JJ human) (NNS HCCs) (NP (NN down-regulation) (NN expression) (JJ 5-AzaC-treated) (NN HCC) (NN cell)))))) (VP (VBP suggest) (NP (NN role) (NN hepatocarcinogenesis)))) |ET| |BS|15:F01.829.316.616 41:A11 52:E02 55:B01.050.150.900.649.801.400.112.400.400 85:G02.111.087.225 104:C04.557.470.200.025.255 249:G05.355.315.800 339:G02.111.087.880|ES| 2:1 19:1 31:1 36:1 94:1 115:1 160:1 257:1 262:1 344:1 441:1 561:1 796:1 900:1 957:1 1132:1 2270:1 2271:1 2272:1 2273:1 2274:1
1 	|BT| (S (NP (PRP We)) (VP (VBD analyzed) (NP (NP (NN cooperation) (NN RB) (NN p53) (NN liver) (NN development) (NN pathogenesis)) (NP (JJ hepatocellular) (NN carcinoma))))) |ET| |BS|2:G05.360.340.024.340.375.249.385 104:C04.557.470.200.025.255 242:A03.620|ES| 12:1 19:1 35:1 303:1 304:1 501:1 836:1 843:1 1168:1 1209:1 1960:1
1 	|BT| (S (NP (PRP We)) (VP (VBD demonstrated) (SBAR (S (NN parkin) (: -) (: /) (: -) (NP (NN mouse) (VBD enhanced) (NN hepatocyte) (NN proliferation)) (VP (VBD developed) (NP (JJ macroscopic) (JJ hepatic) (NN tumor) (JJ characteristic) (JJ hepatocellular) (NN carcinoma))))))) |ET| |BS|11:B01.050.150.900.649.865.635.505.500 104:C04.557.470.200.025.255 262:A11.436.348 515:C04.588.274.623|ES| 7:1 19:1 52:1 299:1 303:1 304:1 336:1 385:1 838:1 843:1 1165:1 1175:1 1909:1 2275:1 2276:1
1 	|BT| (S (NP (PRP We)) (ADVP (RB first)) (VP (VBP show) (SBAR (S (NP (NP (NN Notch-1) (NN receptor)) (, ,) (NP (ADJP (RB well) (JJ downstream)) (NN target) (NN Hes-1)) (, ,)) (VP (VBD up-regulated) (NP (NP (NN colon) (NN cancer) (NN progression)) (, ,) (NP (NP (JJ similar) (NN gene)) (VP (VBN involved) (S (NP (NN chemoresistance))))))))))) |ET| |BS|6:G05.360.340.024.340 16:C23.550.291.656 142:I01.880.604 150:Z01.542.248.960|ES| 2:1 9:1 18:1 19:1 20:1 48:1 113:1 160:1 182:1 186:1 332:1 429:1 560:1 774:1 787:1 816:1 843:1 1301:1 2277:1
1 	|BT| (S (NP (PRP We)) (VP (VBD demonstrated) (NP (NP (NN enhancement) (NN Brf1) (NN Pol) (CD III) (NN gene) (NN expression)) (VBN associated) (NP (NP (NN occurrence) (JJ hepatocellular) (NN carcinoma)) (PRN (-LRB- -LRB-) (NP (NN HCC)) (-RRB- -RRB-))) (NN mouse)))) |ET| |BS|11:B01.050.150.900.649.865.635.505.500 104:C04.557.470.200.025.255 614:G05.360.340.024.340.364.875.667|ES| 9:1 10:1 14:1 19:1 52:1 115:1 169:1 303:1 304:1 441:1 843:1 1175:1 2278:1 2279:1 2280:1 2281:1 2282:1
1 	|BT| (S (NP (PRP We)) (VP (VBP document) (NP (NP (NN cooperation) (NN AEG-1) (NN c-Myc)) (VP (VBG promoting) (NP (NP (NN hepatocarcinogenesis) (VBG analyzing) (JJ hepatocyte-specific) (JJ transgenic) (NN mouse)) (VP (VBG expressing) (NP (CC either) (NP (NP (NN AEG-1)) (PRN (-LRB- -LRB-) (NP (NP (NN albumin)) (PRN (-LRB- -LSB-) (NP (NN Alb)) (-RRB- -RSB-))) (: /) (NP (NN AEG-1)) (-RRB- -RRB-))) (, ,) (NP (NP (NN c-Myc)) (PRN (-LRB- -LRB-) (NP (NN Alb/c-Myc)) (-RRB- -RRB-))) (, ,)))))) (PRN (-LRB- -LRB-) (NP (NNP Alb/AEG) (CD -1) (: /) (NN c-Myc)) (-RRB- -RRB-)))) |ET| |BS|99:B01.050.050.136.500 262:A11.436.348 615:D12.776.034|ES| 2:1 10:1 14:1 19:1 39:1 52:1 285:1 810:1 824:1 843:1 881:1 900:1 1373:1 1378:1 1960:1 1976:1 2283:1 2284:1 2285:1 2286:1 2287:1 2288:1 2289:1 2290:1
1 	|BT| (S (NP (PRP We)) (ADVP (RB previously)) (VP (VBD reported) (NP (NP (JJ hepatic) (NN coexpression) (NN c-Myc) (NN E2F1)) (, ,) (NP (CD 2) (JJ key) (NN regulator) (NN proliferation) (NN apoptosis)) (, ,) (NP (VBD enhanced) (NP (NP (JJ hepatocellular) (NN carcinoma)) (PRN (-LRB- -LRB-) (NP (NN HCC)) (-RRB- -RRB-))) (NN development) (JJ transgenic) (NN mouse))))) |ET| |BS|39:G04.299.139.160 99:B01.050.050.136.500 104:C04.557.470.200.025.255|ES| 2:1 10:1 14:1 19:1 35:1 52:1 89:1 148:1 159:1 235:1 285:1 299:1 303:1 304:1 385:1 441:1 824:1 838:1 843:1 993:1 1527:1 1961:1 2291:1
1 	|BT| (NP (WHADVP (WRB When)) (NP (NP (NP (NN Apc) (NN gene) (NN knockout) (NN mouse)) (PRN (-LRB- -LRB-) (NP (NN APC1309) (NN mouse)) (-RRB- -RRB-))) (VP (VBN given) (NP (CD 600) (CD 1200) (NN p.p.m))))) |ET| |BS|11:B01.050.150.900.649.865.635.505.500 21:G05.360.340.024.340.375.249.050 29:B01.050.050.136.500.500 193:C23.300.825.411 595:G07.203.650.240 596:E02.642.249 616:E05.318.780.074|ES| 2:1 5:1 9:1 10:1 14:1 19:1 29:1 52:1 71:1 109:1 170:1 202:1 280:1 289:1 369:1 370:1 646:1 647:1 781:1 783:1 2191:1 2292:1 2293:1 2294:1 2295:1 2296:1 2297:1 2298:1 2299:1 2300:1 2301:1
